Neuren Wins FDA Orphan Drug Designation for Brain Injury Treatment Candidate
NEU: $20.75 +1.92% · MC: $2.9B
The FDA has granted orphan drug designation to Neuren Pharmaceuticals’ NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, a brain injury caused by insufficient oxygen or blood flow around birth. Neuren is conducting an animal safety study required before a clinical trial and plans to submit an application to begin clinical testing in the first half of 2027. The designation provides incentives including potential marketing exclusivity if the drug is approved.

Comments